Tumors addicted to specific oncoproteins, such as EGFR mutations or ALK translocations, are particularly sensitive to HSP90 inhibition [149], and proteins such as ADI1 and RRP1 have been suggested as indicators confirming HSP90 inhibition through proteomic studies in lung adenocarcinoma models with EGFR/ALK mutations; in addition, proteins such as ASS1, ITCH, and UBE2L3 were suggested to be response predictors for each molecular subtype [150]. The gene discussed is HSP90AA1; the disease is lung adenocarcinoma.